Wachter, Rolf

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","The Open Clinical Trials Journal, 2010, 2, 1-7"],["dc.bibliographiccitation.lastpage","7"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Neumann, Till"],["dc.contributor.author","Sundermeyer, Andreas"],["dc.contributor.author","Esser, Stefan"],["dc.contributor.author","Potthoff, Anja"],["dc.contributor.author","Hower, Martin"],["dc.contributor.author","Ingulf, Becker-Boost"],["dc.contributor.author","Ross, Birgit"],["dc.contributor.author","Jablonka, Robert"],["dc.contributor.author","Neuhaus, Katrin"],["dc.contributor.author","Neumann, Anja"],["dc.contributor.author","Reinsch, Nico"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Müller-Tasch, Thomas"],["dc.contributor.author","Mehrhof, Felix"],["dc.contributor.author","Prettin, Christiane"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Maisch, Bernhard"],["dc.contributor.author","Brockmeyer, Norbert"],["dc.contributor.author","Wasem, Jürgen"],["dc.contributor.author","Dietz, Rainer"],["dc.contributor.author","Erbel, Raimund"],["dc.date.accessioned","2019-07-09T11:53:11Z"],["dc.date.available","2019-07-09T11:53:11Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: An increased life span and the amount of cardiovascular risk factors necessitate a closer look on cardiac diseases in the population of human immunodeficiency virus (HIV) – infected subjects. Therefore, we launched a cardiology driven study analyzing HIV-associated diseases supported by the federal ministry of research. Methods: The HIV-HEART (HIV-infection and HEART disease) study is a prospective and multicenter cohort study performed in an urban area. The study comprehends standardized non-invasive cardiology tests of cardiac diseases, such as laboratory parameter, electrocardiogram, echocardiography and an endurance testing by a six-minute walk test. Results: In a 20 month recruiting period 802 HIV-infected patients (age: 44,2 ± 10,3 years; male: 83,4%) were included into the HIV-HEART Study. Duration of HIV-infection since initial diagnosis was 7,6 ± 5,8 years. Virus load was in 65,6% less than 50 copies/ml and CD4 - cell count (508,8 ± 300,6 cells/􀀁l) was more than 500 cells/􀀁l in 42,6%. A reduced CD4 – cell count between 200 and 499 cells/􀀁l or less than 200 cells/􀀁l was present in 45% and 12, 4%, respectively. Of all participants, 85,2% received antiretroviral therapy, most of these patients NRTIs (96,8%), followed by PIs (48,5%), and NNRTIs (45,7%). Conclusions: The characteristics of the HIV-HEART Study cohort are comparable to other national or international cohort registers on HIV-infected persons, performed in industrialized countries. Therefore, the HIV-HEART Study will be able to yield reliable data on the performance of HIV-associated diseases. (Clinical Trials NCT01119729)."],["dc.identifier.doi","10.2174/1876821001001020001"],["dc.identifier.fs","576761"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6976"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60358"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1876-8210"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Recruiting and Baseline of the HIV-HEART Study: A Prospective, Multicenter Trial to Analyze Cardiac Diseases in HIV-Infected Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","588"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","597"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Fonseca, Ana F."],["dc.contributor.author","Balas, Bogdan"],["dc.contributor.author","Kap, Elisabeth"],["dc.contributor.author","Engelhard, Johanna"],["dc.contributor.author","Schlienger, Raymond"],["dc.contributor.author","Klebs, Sven"],["dc.contributor.author","Wirta, Sara Bruce"],["dc.contributor.author","Kostev, Karel"],["dc.date.accessioned","2019-09-30T14:05:10Z"],["dc.date.accessioned","2021-10-27T13:21:21Z"],["dc.date.available","2019-09-30T14:05:10Z"],["dc.date.available","2021-10-27T13:21:21Z"],["dc.date.issued","2019"],["dc.description.abstract","AIMS: To analyse real-world treatment patterns of sacubitril/valsartan (sac/val) using data from a pharmacy database in Germany. METHODS AND RESULTS: A retrospective cohort study of 26 191 adult patients (aged ≥ 18 years) in the IMS® longitudinal prescriptions database in Germany who were dispensed sac/val from January 2016 to June 2017 was conducted. The analysis included sac/val dose titration assessed in the 6 months from first sac/val prescription; prescriptions of concomitant cardiovascular medications in the 6 months pre- and post-index and compliance and persistence during 12 months post-index. Two-thirds of patients were prescribed the lowest sac/val dose of 50 mg twice daily (b.i.d.) at index and up-titration during the first 6 months was attempted in 41% of these patients. Ten percent of patients prescribed 200 mg b.i.d. at index had to be stably down-titrated; among patients prescribed 50 or 100 mg b.i.d. at index that were up-titrated, > 80% remained on the higher dose. Overall, the mean daily diuretic dose decreased by 25% after initiation of sac/val. High compliance and persistence rates were observed across sac/val doses, increasing with higher sac/val dose at index. Prior dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker had only minor impact on first sac/val dose, compliance and persistence. CONCLUSIONS: Most patients prescribed sac/val are not initiated on the recommended dose nor up-titrated as recommended by the EU Summary of Product Characteristics. Initiation of sac/val was associated with high persistence and compliance and a dose reduction of diuretics. Barriers to up-titration must be explored."],["dc.identifier.doi","10.1002/ejhf.1465"],["dc.identifier.pmid","30972918"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16444"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92015"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1879-0844"],["dc.relation.issn","1879-0844"],["dc.relation.issn","1388-9842"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0216530"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Wasser, Katrin"],["dc.contributor.author","Weber-Krüger, Mark"],["dc.contributor.author","Jürries, Falko"],["dc.contributor.author","Liman, Jan"],["dc.contributor.author","Hamann, Gerhard F."],["dc.contributor.author","Kermer, Pawel"],["dc.contributor.author","Uphaus, Timo"],["dc.contributor.author","Protsenko, Evgeny"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Mende, Meinhard"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2019-07-09T11:51:30Z"],["dc.date.available","2019-07-09T11:51:30Z"],["dc.date.issued","2019"],["dc.description.abstract","BACKGROUND: The cardiac diagnostic workup of stroke patients, especially the value of echocardiography and enhanced and prolonged Holter-ECG monitoring, is still a matter of debate. We aimed to analyse the impact of pathologies detected by echocardiography and ECG monitoring on therapeutic decisions and prognosis. METHODS: Find-AFRANDOMISED was a prospective multicenter study which randomised 398 acute ischemic stroke patients ≥ 60 years to enhanced and prolonged Holter-ECG monitoring or usual stroke unit care. This substudy compared therapeutic consequences of echocardiography and routine Holter-ECG or enhanced and prolonged Holter-ECG monitoring, respectively, and prognosis of patients with or without pathologic findings in echocardiography or Holter-ECG monitoring. RESULTS: 50.3% received enhanced and prolonged Holter-ECG monitoring and 49.7% routine ECG monitoring. 82.9% underwent transthoracic echocardiography (TTE), 38.9% transesophageal echocardiography (TEE) and 25.6% both procedures. 14/89 TEE pathologies and 1/90 TTE pathology led to a change in therapy, resulting in a number needed to change decision (NNCD) of 12 and 330 (p < 0.001), respectively. In comparison, enhanced and prolonged Holter-ECG monitoring found atrial fibrillation (AF) in 27 of 200 patients, and routine ECG monitoring in twelve of 198 patients, leading to therapeutic changes in all patients (NNCD 8 and 17, respectively, p < 0.001). CONCLUSIONS: Most changes in therapeutic decisions were triggered by enhanced and prolonged Holter-ECG monitoring, which should therefore play a more prominent role in future guidelines. Echocardiography identifies a patient group at high cardiovascular risk, but rarely result in therapeutic changes. Whether this patient group requires further cardiovascular workup remains unknown. This should be further investigated by interdisciplinary neurocardiologic teams and in appropriate future trials."],["dc.identifier.doi","10.1371/journal.pone.0216530"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16141"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59961"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","The cardiac diagnostic work-up in stroke patients—A subanalysis of the Find-AFRANDOMISED trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","248"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Psychosomatics"],["dc.bibliographiccitation.lastpage","256"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Meyer, Thomas"],["dc.contributor.author","Stanske, Beate"],["dc.contributor.author","Kochen, Michael M."],["dc.contributor.author","Cordes, Andreas"],["dc.contributor.author","Yüksel, Iraz"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Lüers, Claus"],["dc.contributor.author","Scherer, Martin"],["dc.contributor.author","Binder, Lutz"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.date.accessioned","2019-07-09T11:52:56Z"],["dc.date.available","2019-07-09T11:52:56Z"],["dc.date.issued","2010"],["dc.description.abstract","BACKGROUND: Vital exhaustion, a psychological state characterized by unusual fatigue, irritability, and feelings of demoralization, has been identified as a risk factor for cardiovascular diseases and linked to elevated levels of pro-inflammatory cytokines. OBJECTIVE: The purpose of this study was to investigate the relationship between vital exhaustion and cytokine levels in patients with cardiovascular risk factors. METHOD: The entire cohort consisted of 356 primary-care patients with cardiovascular risk factors who participated in a study of early recognition of heart failure. All participants completed the Maastricht questionnaire (MQ) for assessing vital exhaustion. Cytokine serum levels were measured in all those subjects (N=178) who were assigned to the highest and lowest quartiles of the MQ, respectively. RESULTS: We found that elevated serum concentrations of IL-6, TNFα, and IL-10, but not IL-1β or natriuretic peptides were associated with high MQ scores indicative of vital exhaustion. Using logistic regression analyses controlling for clinical variables and Type D personality, both TNFα (multivariate odds ratio [OR] =1.86; 95%-confidence interval [CI] =1.30-2.68; p=0.001) and IL-10(OR=1.62; 95%-CI=1.15-2.28; p=0.006), but not other cytokines significantly predicted vital exhaustion independently of other clinical and laboratory parameters examined [corrected]. CONCLUSION: The subjective state of vital exhaustion is linked to a substantial alteration in the pattern of secreted cytokines. Data suggest that a disturbance in the levels of both pro-inflammatory and anti-inflammatory mediators, rather than isolated stimulation by pro-inflammatory cytokines, is associated with the mental and physical changes of vital exhaustion."],["dc.identifier.doi","10.1176/appi.psy.51.3.248"],["dc.identifier.fs","573439"],["dc.identifier.pmid","20484723"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60303"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1545-7206"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.subject.mesh","Aged"],["dc.subject.mesh","Austria"],["dc.subject.mesh","Cardiovascular Diseases"],["dc.subject.mesh","Cohort Studies"],["dc.subject.mesh","Coronary Disease"],["dc.subject.mesh","Fatigue"],["dc.subject.mesh","Female"],["dc.subject.mesh","Heart Failure"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Interleukin-10"],["dc.subject.mesh","Interleukin-6"],["dc.subject.mesh","Irritable Mood"],["dc.subject.mesh","Male"],["dc.subject.mesh","Middle Aged"],["dc.subject.mesh","Morale"],["dc.subject.mesh","Personality Inventory"],["dc.subject.mesh","Primary Health Care"],["dc.subject.mesh","Psychometrics"],["dc.subject.mesh","Risk Factors"],["dc.subject.mesh","Tumor Necrosis Factor-alpha"],["dc.title","Elevated serum levels of interleukin-10 and tumor necrosis factor α [corrected] are both associated with vital exhaustion in patients with cardiovascular risk factors."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Platschek, Lars"],["dc.contributor.author","Holzendorf, Volker"],["dc.contributor.author","Pilz, Stefan"],["dc.contributor.author","Tomaschitz, Andreas"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Angermann, Christiane E"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2019-07-09T11:50:12Z"],["dc.date.available","2019-07-09T11:50:12Z"],["dc.date.issued","2019"],["dc.description.abstract","AIMS: Vitamin D deficiency is prevalent in heart failure (HF), but its relevance in early stages of heart failure with preserved ejection fraction (HFpEF) is unknown. We tested the association of 25-hydroxyvitamin D [25(OH)D] serum levels with mortality, hospitalizations, cardiovascular risk factors, and echocardiographic parameters in patients with asymptomatic diastolic dysfunction (DD) or newly diagnosed HFpEF. METHODS AND RESULTS: We measured 25(OH)D serum levels in outpatients with risk factors for DD or history of HF derived from the DIAST-CHF study. Participants were comprehensively phenotyped including physical examination, echocardiography, and 6 min walk test and were followed up to 5 years. Quality of life was evaluated by the Short Form 36 (SF-36) questionnaire. We included 787 patients with available 25(OH)D levels. Median 25(OH)D levels were 13.1 ng/mL, mean E/e' medial was 13.2, and mean left ventricular ejection fraction was 59.1%. Only 9% (n = 73) showed a left ventricular ejection fraction <50%. Fifteen per cent (n = 119) of the recruited participants had symptomatic HFpEF. At baseline, participants with 25(OH)D levels in the lowest tertile (≤10.9 ng/L; n = 263) were older, more often symptomatic (oedema and fatigue, all P ≤ 0.002) and had worse cardiac [higher N-terminal pro-brain natriuretic peptide (NT-proBNP) and left atrial volume index, both P ≤ 0.023], renal (lower glomerular filtration rate, P = 0.012), metabolic (higher uric acid levels, P < 0.001), and functional (reduced exercise capacity, 6 min walk distance, and SF-36 physical functioning score, all P < 0.001) parameters. Increased NT-proBNP, uric acid, and left atrial volume index and decreased SF-36 physical functioning scores were independently associated with lower 25(OH)D levels. There was a higher risk for lower 25(OH)D levels in association with HF, DD, and atrial fibrillation (all P ≤ 0.004), which remained significant after adjusting for age. Lower 25(OH)D levels (per 10 ng/mL decrease) tended to be associated with higher 5 year mortality, P = 0.05, hazard ratio (HR) 1.55 [1.00; 2.42]. Furthermore, lower 25(OH)D levels (per 10 ng/mL decrease) were related to an increased rate of cardiovascular hospitalizations, P = 0.023, HR = 1.74 [1.08; 2.80], and remained significant after adjusting for age, P = 0.046, HR = 1.63 [1.01; 2.64], baseline NT-proBNP, P = 0.048, HR = 1.62 [1.01; 2.61], and other selected baseline characteristics and co-morbidities, P = 0.043, HR = 3.60 [1.04; 12.43]. CONCLUSIONS: Lower 25(OH)D levels were associated with reduced functional capacity in patients with DD or HFpEF and were significantly predictive for an increased rate of cardiovascular hospitalizations, also after adjusting for age, NT-proBNP, and selected baseline characteristics and co-morbidities."],["dc.identifier.doi","10.1002/ehf2.12413"],["dc.identifier.pmid","30784226"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15880"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59721"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2055-5822"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0181766"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Ammermann, Antje"],["dc.contributor.author","Ganser, Janina"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2019-07-09T11:43:38Z"],["dc.date.available","2019-07-09T11:43:38Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: Patients with retinal vascular occlusion disease have an increased risk for ischemic stroke and share some risk factors with cerebrovascular disease. The purpose of this study was to analyze the prevalence of atrial fibrillation (AF) in subjects with retinal vascular occlusive disease and anterior ischemic optic neuropathy and to compare these data to an ischemic stroke group. METHODS: Prospective, observational single-center trial. Subjects with retinal artery occlusion (RAO), retinal vein occlusion (RVO) and anterior ischemic optic neuropathy (AION) were included. Patients with ischemic stroke (IS) from a previous observational trial were used as control. Investigation included 7-day Holter ECG, echocardiography, duplex ultrasonography of the carotid arteries, and 24-hour blood pressure monitoring. Further vascular risk factors were documented. RESULTS: During the 1-year study period, 101 patients were recruited. The control group with ischemic stroke consisted of 272 subjects. At inclusion, the prevalence of AF was 12% (RAO), 10.2% (RVO), 11.1% (NAION) and 15.8% (IS). The final prevalence after Holter ECG rose to 16% (RAO), 18.4% (RVO), 14.8% (NAION) and 26.5% (IS). No significant difference was measured between groups. CONCLUSIONS: We detected a similar prevalence of AF in all groups. RVO patients tended to exhibit a higher AF detection rate and lower number needed to screen than RAO and NAION. The detection of AF rose considerably via Holter ECG. As a consequence, we recommend prolonged ECG monitoring in patients with acute ophthalmic vascular diseases."],["dc.identifier.doi","10.1371/journal.pone.0181766"],["dc.identifier.pmid","28771491"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14599"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58930"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]